To the Editor: Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome results (LEADER) trial illustrated that among patients with type 2 diabetes mellitus, those in the liraglutide group… Click to show full abstract
To the Editor: Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome results (LEADER) trial illustrated that among patients with type 2 diabetes mellitus, those in the liraglutide group had lower rates of cardiovascular events and death from any cause than did those in the placebo group.[1] Herein, we reported a case of an increase of heart rate (HR) and electrocardiographic changes after subcutaneous liraglutide.
               
Click one of the above tabs to view related content.